XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

Expanding store network for ASX listed retailer

Sales growth but lack of margin expansion due to competition.
stocks

3 cheap fully franked stocks

Discounted Aussie shares that offer a tax rebate.
stocks

SpaceX jumps 19% in debut, but hurdles lie ahead

Pre-IPO holders could start selling later this summer, and earnings will be an important test.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,128.0014.600.16%
CAC 408,384.0133.140.40%
DAX 4024,894.01258.711.05%
Dow JONES (US)51,671.03468.770.92%
FTSE 10010,430.6241.10-0.39%
HKSE24,842.67124.570.50%
NASDAQ26,683.94795.103.07%
Nikkei 22569,317.503,297.464.99%
NZX 50 Index13,420.2959.700.45%
S&P 5007,554.29122.831.65%
S&P/ASX 2008,914.007.000.08%
SSE Composite Index4,096.4764.961.61%

Market Movers